Results 21 to 30 of about 2,565,028 (307)

Umbilical cord blood: A promising source for allogeneic CAR-T cells

open access: yesFrontiers in Oncology, 2022
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed and refractory acute lymphoblastic leukemia (R/R ALL). However, autologous CAR-T cells derived from patients with B-ALL often show poor amplification ability ...
Dian-Dian Liu   +21 more
doaj   +1 more source

Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. [PDF]

open access: yes, 2014
OBJECTIVES: The GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) study is designed to determine the safety, efficacy, and cost-effectiveness of a strategy of adjusting therapy with the goal of achieving and
Adams, Kirkwood F.   +15 more
core   +3 more sources

Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase

open access: yesPharmaceuticals, 2021
Periodontitis is a severe yet underestimated oral disease. Since it is linked to several systemic diseases, such as diabetes, artheriosclerosis, and even Alzheimer’s disease, growing interest in treating periodontitis has emerged recently.
Daniel Ramsbeck   +5 more
doaj   +1 more source

Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia

open access: yesJournal of Pharmacological Sciences, 2019
Acute myeloid leukemia (AML) is the most common subtype of hematological malignancy in humans, and its incidence increases with age. The treatment of AML still faces challenges.
Wenjing Ma   +10 more
doaj   +1 more source

Next-Generation Sequencing: Targeting Targeted Therapies [PDF]

open access: yesClinical Cancer Research, 2015
Abstract Next-generation sequencing (NGS) has given new perspective in oncology. With the ongoing development of targeted therapies, NGS is evolving molecular diagnostics by providing comprehensive interrogation of clinically actionable genomic aberrations in tumors.
Justine N, McCutcheon   +1 more
openaire   +2 more sources

Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro

open access: yesMolecules, 2020
Alzheimer’s disease (AD) and Parkinson’s disease (PD), including dementia with Lewy bodies (DLB), account for the majority of dementia cases worldwide.
Janett Köppen   +14 more
doaj   +1 more source

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours [PDF]

open access: yes, 2015
Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy.
Alajati, Abdullah   +25 more
core   +1 more source

Targeting BCL-2 regulated apoptosis in cancer [PDF]

open access: yes, 2018
The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death ...
Campbell, Kirsteen J.   +1 more
core   +1 more source

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. [PDF]

open access: yes, 2017
Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target.
DeVere White, Ralph W   +11 more
core   +1 more source

Accuracy of a magnetic resonance imaging‐based 3D printed stereotactic brain biopsy device in dogs [PDF]

open access: yes, 2020
Background: Brain biopsy of intracranial lesions is often necessary to determine specific therapy. The cost of the currently used stereotactic rigid frame and optical tracking systems for brain biopsy in dogs is often prohibitive or accuracy is not ...
Böttcher, Peter   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy